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ABSTRACT
Aims/Introduction: We investigated the safety of the batteries and power units used
in insulin pumps in Japan.
Materials and Methods: A self-administered questionnaire was sent to the 201 mem-
bers of the Association for Innovative Diabetes Treatment in Japan.
Results: A total of 56 members responded, and among the 1,499 active devices, 66
had episodes of trouble related to the batteries and power units. The ratio of reported
troubles to the number of insulin pumps was significantly higher in insulin pumps with a
continuous glucose monitoring sensor compared with insulin pumps without a continu-
ous glucose monitoring sensor (odds ratio 2.82, P < 0.05). The cause and the conse-
quences varied. The brands of the batteries varied; alkaline batteries purchased at drug
stores and other shops accounted for 19.7%. Termination of battery life within 72 h of
use was reported most frequently (50.0%), suspension of the insulin pump (21.2%) and
leakage of the battery fluid (4.5%) followed. A total of 53.2% of the reported insulin
pumps needed to be replaced, and 37.1% of them recovered after replacement of the
battery.
Conclusions: As trouble related to the batteries and power units of insulin pumps was
frequent, practical guidance should be provided to respective patients regarding the use
of reliable batteries, and to be well prepared for unexpected insulin pump failure.
INTRODUCTION
Insulin pump therapy, or continuous subcutaneous insulin infu-
sion, consists of an infusion set with an insulin reservoir, a tube
and a cannula, pumping mechanism, computer chip, screen,
casing, and battery. The prevalence of insulin pump therapy for
patients with type 1 diabetes mellitus is increasing in many
countries. Rapid-acting insulin analog is used in the insulin
pump, and it is infused subcutaneously to mimic physiological
insulin secretion1. Pharmacokinetic studies showed that the
rapid-acting insulin analog acts within 15 min, peaks in 1 h
and disappears within 4 h after subcutaneous injection2. Insulin
infusion failure is a critical problem in insulin pump therapy
because of a small amount of subcutaneous residual insulin3,4.
Once the insulin infusion is accidentally stopped, patients start
to develop diabetic ketoacidosis within 5–6 h5. Therefore, it is
very important that insulin infusion is maintained during insu-
lin pump therapy. We sometimes experience diabetic ketoacido-
sis caused by insulin pump malfunctions, such as the
obstruction of the infusion set or the dislocation of the cannula
from the skin, and, as the majority of type 1 diabetes mellitus
patients require insulin to maintain their lives, the loss of func-
tion of insulin pumps can become a fatal problem6. However,
the incidence and the causes of battery and power unit failure
during insulin pump therapy have been rarely published toReceived 4 August 2017; revised 2 October 2017; accepted 16 October 2017
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date. Batteries sold at drug stores and other shops are cheap,
and sometimes the manufacturers are not identifiable. There-
fore, the Association for Innovative Diabetes Treatment in
Japan (ASINDTJ) decided to investigate the prevalence of trou-
ble regarding batteries and power units used in insulin pumps.
METHODS
Study design and participants
A multicenter, cross-sectional survey regarding the safety of
batteries and power units used in insulin pumps was carried
out among ASINDTJ members. The questionnaire used for the
survey was designed by the authors, and underwent content
and construct validation by the organizers of the association. A
self-administered questionnaire was mailed to all the 201 mem-
bers (physicians 85.6%, registered nurses 3.5%, pharmacists
3.0%, laboratory technicians 3.0%, registered dieticians 2.0%,
other occupations 3.0%) across Japan in 2016. The following
variables were assessed: type of insulin pump, number of bat-
tery and power unit problems, combination of continuous glu-
cose monitoring (CGM; yes/no), year of the problem, type of
battery, cause of the problem and actions required to resolve
the troubles.
Statistical analysis
All statistical analysis was carried out using R (R Foundation
for Statistical Computing, Vienna, Austria)7. We reported data
for categorical variables, such as percentages, odds ratios and
95% confidence intervals (CI). We compared the characteris-
tics of insulin pumps with or without a CGM sensor using
Fisher’s exact test. P-values of <0.05 were considered signifi-
cant.
Ethics
As the present study was strictly limited to information about
insulin pumps and contains no information about the patients
wearing them, ASINDTJ decided that this study did not need
to be approved by an ethics committee.
RESULTS
A total of 56 members of the ASINDTJ responded to the ques-
tionnaire. As of 1 September 2016, MiniMed 620G, Paradigm
722 and Paradigm 712 (Medtronic MiniMed, Inc., Northridge,
CA, USA) were mainly used in Japan, and a small number of
TOP-8100 and TOP-8200 (TOP Corporation, Tokyo, Japan)
were used (Table S1). Just 14.3% of the respondents supplied
the batteries for insulin pumps to patients. Among them,
12.5% purchased the batteries at a medical institution, and
87.5% were provided batteries by the sales representatives
involved in the leasing contract of the insulin pumps. Regard-
ing the supplier of the batteries, 62.5% wished that the batteries
be included in the leasing contract of the insulin pumps.
Regarding reasons, 80% expected the supply of appropriate bat-
teries, 65.7% thought pump users would not have to purchase
the batteries themselves and 60% expected the possibility of
using poor quality batteries would be reduced (multiple answers
were accepted).
A total of 24 ASINDTJ members reported troubles occurring
in the batteries and power units, and the reports on MiniMed
620G with CGM sensor were most common (Table 1). There
were 44 cases out of 639 insulin pumps with a CGM sensor
([1] in Table 1), and 22 cases out of 860 insulin pumps with-
out a CGM sensor ([2]–[7] in Table 1). The ratio of reports
regarding problems related to the batteries and the power units
to the number of insulin pumps was significantly higher in
insulin pumps with a CGM sensor compared with insulin
pumps without a CGM sensor (odds ratio 2.82, 95% CI 1.67–
4.75, P < 0.05). The reported problems were mainly in 2015
and 2016, and many of the problems occurred in the MiniMed
620G with a CGM sensor (Table S2).
The brands of the batteries varied; and alkaline batteries pur-
chased at drug stores, hundred-yen stores, volume-sales elec-
tronics retailers and DIY stores accounted for 19.7% of the
report (Tables 2 and S3). Regarding the types of trouble related
to the batteries and the power units, termination of the battery
life within 72 h of use was reported most frequently (50.0%),
suspension of the insulin pump (21.2%) and leakage of the bat-
tery fluid (4.5%) followed (Tables 3 and S4). An error message
generated by the MiniMed 620G with a CGM sensor, ‘Error
25’ (power error detected), was reported most frequently
(Tables 4 and S5). Regarding the actions required to resolve
the trouble, 53.2% of the reported insulin pumps needed to be
replaced, 37.1% of them recovered after replacement of the bat-
tery and 9.7% of them recovered by following the manufac-
turer’s instructions, including telephone support (Table S6).
DISCUSSION
In the present study, the rate of trouble related to the batteries
and power units used in insulin pumps was approximately 5%
among all active devices. The ratio of reports related to the bat-
teries and power units of the insulin pumps to their total num-
ber was significantly higher in insulin pumps with a CGM
sensor (sensor-augmented pumps) compared with insulin
pumps without a CGM sensor.
The reported troubles occurred mainly in 2015 and 2016,
and this might be related to the fact that sensor-augmented
pumps became commercially available in Japan from February
2015.
As this survey does not include information regarding the
numbers, periods, manufacturers and brands of the batteries
used in pumps without the batteries and the power unit prob-
lem, the rate of occurrence is unclear. However, considering the
generally accepted idea that the batteries used in insulin pumps
should be reliable, it might be better to recommend that insulin
pump users choose batteries from well-known manufacturers
rather than those of unidentified manufacturers.
It is important to note that approximately 20% of the report
resulted in the suspension of the insulin pumps, which could
potentially have caused severe adverse events including
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hyperglycemia, diabetic ketoacidosis or death in absolutely insu-
lin-dependent patients if appropriate actions, such as changing
the batteries or injecting insulin using alternative devices, had
not been taken within an adequate time to resolve the trouble.
It is also important to note that approximately 5% of the
reports resulted in the leakage of battery fluid inside the insulin
pumps, which could potentially lead to a complete loss of func-
tion of the devices including the alarm function.
Batteries are not the only cause of power unit-related prob-
lems. For example, approximately 40% of the error messages
generated by MiniMed 620G with a CGM sensor were ‘Error
25.’ This ‘Error 25’ is caused by the interference of the software
operating the pump, and indicates drainage of the internal
rechargeable battery due to the disturbance in its charging pro-
cess. Some of the early termination of battery life might be
related to the software that diagnoses the decline of battery
power. As MiniMed 620G pumps were designed and built in
the USA, it is not clear which battery available in Japan is really
suited to use with the device. Medtronic started to sell alkaline
batteries manufactured by Energizer (St. Louis, MO, USA) as
the recommended battery to use with its pumps from January
2017 in Japan. Further evaluation is required to specify other
recommendable batteries from different manufacturers.
The reason why almost half of the insulin pumps with bat-
tery and power unit problems needed to be replaced in the pre-
sent study is unclear. Medtronic disclosed that it replaces
insulin pumps with multiple episodes of ‘Error 25.’ Medtronic
has updated the software version of the MiniMed 620G from
2.6B to 2.9B to reduce ‘Error 25’; however, the effect is
unknown at this moment.
From the present study, we would like to propose that bat-
tery- and the power unit-related problems are frequent events.
It is worth noting the special background of insulin pump pre-
scription in Japan. Unlike in the USA, insulin pumps are leased
to patients from medical institutions due to the monthly health
insurance reimbursement system. The majority of the insulin
pumps are subleased from medical institutions, to which insulin
pumps are leased by the representative sales companies. Some
of the insulin pumps are purchased by the institutions and






(1) MiniMed 620G with CGM sensor 44 639 6.9
(2) MiniMed 620G without CGM sensor 4 207 1.9
(3) Paradigm 722 14 568 2.5
(4) Paradigm 712 3 64 4.7
(5) TOP-8200 0 4 0.0
(6) TOP-8100 0 2 0.0
(7) Others 1 15 6.7
Total 66 1,499 4.4
(1) Insulin pumps with continuous glucose monitoring (CGM) sensor.
(2)–(7) Insulin pumps without CGM sensor.
Table 2 | Details of the batteries in the reported trouble cases







(2) Alkali battery Panasonic Evolta 13 19.7




Fujitsu Premium 1 1.5
Maxell Voltage 1 1.5
Toshiba Alkali1 3 4.5
Batteries purchased at drug
store, hundred-yen store,
volume-sales electronics













Table 3 | Types of trouble related to the batteries and the power units
n Rate (%)
(1) Termination of battery life within 72 h of use 33 50.0
(2) Suspension of the insulin pump 14 21.2
(3) Leakage of the battery fluid 3 4.5
(4) Usage of inappropriate batteries 1 1.5
(5) Others 15 22.7
Total 66 100
Table 4 | Types of error message (MiniMed 620G with continuous
glucose monitoring sensor)
n Rate (%)
(1) Power error detected (Error 25) 17 38.6
(2) Insert battery (Delivery stopped) 2 4.5
(3) Low battery (Replace battery soon) 15 34.1
(4) Replace battery now (Delivery stopped) 4 9.1
(5) Replace battery (Battery life less than 30 min) 2 4.5
(6) Battery not compatible 0 0.0
(7) Battery failed (Insert a new battery) 1 2.3
(8) Pump error (Delivery stopped) 1 2.3
(9) Others 4 9.1
Total 46 100
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leased to the patients, but this is a minority. When governmen-
tal regulations regarding the health insurance reimbursement of
insulin pump therapy are strictly interpreted, medical institu-
tions need to supply all the consumables to the patients. This
means not only the infusion sets, but also batteries need to be
provided to the patients; however, the reality is that only a lim-
ited number of medical institutions are executing this, as shown
in the present study.
There are several previous studies that surveyed insulin
pump failure; however, detailed information related to batteries
and power units is limited. A prospective study carried out in
France reported that there were 26 cases of ‘defect in reservoir
or battery compartment’ among 42 mechanical defects,
accounting for 18% of the 232 entire insulin pump failures
including complete pump failure, alarm set off and minor
defect8. A cross-sectional study using a self-report questionnaire
completed by patients in the UK reported ‘battery compart-
ment problem’ accounted for 11% of the insulin pump mal-
function9. However, in these studies, it was unclear how much
of the battery compartment problem was related to the batteries
themselves rather than the problem of the insulin pump enclo-
sure. A prospective study of pediatric and adolescent patients
in Australia and New Zealand surveying various adverse events
including pump malfunctions, set/site related, severe hypo-
glycemia and cutaneous problems reported adverse events up
to 40 out of 100 person-years, of which ‘battery issue’
accounted for 6%; that is, frequency of 2.4 out of 100 person-
years10. Another prospective study carried out in France
reported that the incidence rate of insulin pump malfunctions
was 33 out of 100 pump-years, and mechanical defect
accounted for 35% of the reported malfunctions; however, the
proportion of the trouble related to batteries and power units
was not described11. In the present study, 53.2% of the insulin
pumps with problems in the batteries or power units needed to
be replaced. A retrospective study carried out in Italy reported
that 0.165 insulin pump replacements per patient-year were
experienced in children and adolescents with type 1 diabetes,
and Animas VIBE (Animas Corporation, West Chester, PA,
USA) and MiniMed VEO (Medtronic MiniMed, Inc., North-
ridge, CA, USA), both with CGM connectivity, were the most
replaced in this survey, but the difference between sensor-aug-
mented pumps and insulin pumps without a CGM sensor did
not reach statistical significance12.
A limitation of the present study was its cross-sectional
observational design, lacking information about the frequency
of troubles and patient background, together with a low
response rate (27.9%). There is the possibility of missed reports
that can affect the number of incidents, because the self-admi-
nistered questionnaire was not sent to the patients directly, and
the actual number of incidents might be much larger than that
described in this report. A prospective study regarding the
safety of the batteries and power units used in insulin pumps
would be valuable to further clarify the frequency of such
problems.
As the troubles related to the batteries and power units of
insulin pumps were frequent, practical guidance should be pro-
vided to respective patients to use reliable batteries, and to be
well prepared for unexpected insulin pump failure. As some of
the insulin pumps recovered after following the manufacturer’s
instructions, reminding patients to keep the telephone number
of the manufacturer’s telephone support at hand might be help-
ful. If the electricity supply to the insulin pump is completely
lost, the alarm function could no longer be activated. Executing
self-monitoring of blood glucose four times a day or more, a
standard procedure required for safe continuous subcutaneous
insulin infusion, might help in finding insulin pump failure in
such situations. Once insulin pump failure occurs, injecting
insulin with insulin pens is important to prevent hyperglycemia
and diabetic ketoacidosis. So far, the safety of the battery and
power units used in insulin pumps has not been widely dis-
cussed. However, we believe that this is a very important issue
related to the safety and the effectiveness of continuous subcu-
taneous insulin infusion.
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Additional Supporting Information may be found in the online version of this article:
Table S1 | Number of insulin pumps and their models.
Table S2 | Years in which the reported trouble occurred.
Table S3 | Details of the batteries in the reported trouble cases.
Table S4 | Types of trouble related to the batteries and the power units.
Table S5 | Types of error message.
Table S6 | Actions required to resolve the trouble.
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